Are New β-Lactam/β-Lactamase Inhibitor Combinations Promising Against Carbapenem-Resistant <i>K. pneumoniae</i> Isolates?

ABSTRACT:

Background/objectives

Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections present a significant clinical challenge due to limited therapeutic options and high transmission potential. This study aimed to identify the resistance genes associated with carbapenemase production in CRKP isolates and evaluate the in vitro activity of ceftazidime/avibactam (CZA) and meropenem/vaborbactam (MEV), among other β-lactam/β-lactamase inhibitor combinations.

Methods

Between October 2021 and June 2022, a total of 504 CRKP isolates were grown from patient samples in intensive care units. When duplicate patient samples were removed, the remaining 89 isolates were included in the study. Bacterial identification and antimicrobial susceptibility testing were per-formed using MALDI

SUBMITTER: Ceylan AN 

PROVIDER: S-EPMC11944681 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature